

S2 Table. Initial treatment modalities of NSCLC patients according to clinical stage in the year 2015

	Total	Non-survivor	Survivor	p-value
Stage I	390	91	299	
Surgery	303 (77.7)	37 (40.7)	266 (89.0)	< 0.001
RT only	18 (4.6)	12 (13.2)	6 (2.0)	< 0.001
CCRT	6 (1.5)	4 (4.4)	2 (0.7)	0.011
Chemotherapy	25 (6.4)	13 (14.3)	12 (4.0)	< 0.001
Best supportive care	22 (5.6)	17 (18.7)	5 (1.7)	< 0.001
Unknown	2 (0.5)	2 (2.2)	0	0.010
Stage II	261	122	139	
Surgery	118 (45.2)	25 (20.5)	93 (66.9)	< 0.001
RT only	34 (13.0)	23 (18.9)	11 (7.9)	0.009
CCRT	13 (5.0)	10 (8.2)	3 (2.2)	0.025
Chemotherapy	38 (14.6)	17 (13.9)	21 (15.1)	0.789
Best supportive care	45 (17.2)	35 (28.7)	10 (7.2)	< 0.001
Unknown	3 (1.1)	3 (2.5)	0	0.063
Stage III	653	559	94	
Surgery	38 (5.8)	18 (3.2)	20 (21.3)	< 0.001
RT only	59 (9.0)	56 (10.0)	3 (3.2)	0.033
CCRT	148 (22.7)	121 (21.6)	27 (28.7)	0.129
Chemotherapy	106 (16.2)	94 (16.8)	12 (12.8)	0.325
Best supportive care	189 (28.9)	174 (31.1)	15 (16.0)	0.003
Unknown	24 (3.7)	21 (3.8)	3 (3.2)	0.788
Stage IV	514	471	43	
Surgery	26 (5.1)	15 (3.2)	11 (25.6)	< 0.001
RT only	37 (7.2)	34 (7.2)	3 (7.0)	0.953
CCRT	43 (8.4)	42 (8.9)	1 (2.3)	0.135
Chemotherapy	118 (23.0)	113 (24.0)	5 (11.6)	0.065
EGFR inhibitors	86 (16.7)	75 (15.9)	11 (25.6)	0.492
ALK inhibitors	11 (2.1)	8 (1.7)	3 (7.0)	0.207
Best supportive care	180 (35.0)	171 (36.3)	9 (20.9)	0.043
Unknown	13 (2.5)	13 (2.8)	0	0.270

Values are presented as the number (%). ALK, anaplastic lymphoma kinase; CCRT, concurrent chemoradiation therapy; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; RT, radiation therapy.